These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 19485758)

  • 21. Towards a Preventive Strategy for Toxoplasmosis: Current Trends, Challenges, and Future Perspectives for Vaccine Development.
    Fereig RM; Nishikawa Y
    Methods Mol Biol; 2016; 1404():153-164. PubMed ID: 27076296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immune response in BALB/c mice induced by a suicidal DNA vaccine of the MIC3 gene of Toxoplasma gondii.
    Fang R; Nie H; Wang Z; Tu P; Zhou D; Wang L; He L; Zhou Y; Zhao J
    Vet Parasitol; 2009 Oct; 164(2-4):134-40. PubMed ID: 19592172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in Toxoplasma gondii immunotherapeutics.
    Lim SS; Othman RY
    Korean J Parasitol; 2014 Dec; 52(6):581-93. PubMed ID: 25548409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryopreservation of an attenuated vaccine strain of the protozoan parasite Toxoplasma gondii.
    Booth KS; James ER; Popiel I
    Cryobiology; 1996 Jun; 33(3):330-7. PubMed ID: 8689890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The vaccines against toxoplasmosis--current status of the studies].
    Długońska H; Gatkowska J; Kur J; Gasior A
    Wiad Parazytol; 2007; 53(3):195-201. PubMed ID: 18075151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxoplasma gondii: proteomic analysis of antigenicity of soluble tachyzoite antigen.
    Ma GY; Zhang JZ; Yin GR; Zhang JH; Meng XL; Zhao F
    Exp Parasitol; 2009 May; 122(1):41-6. PubMed ID: 19545523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further analysis of protection induced by the MIC3 DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both Lectin-like and EGF-like domains of MIC3 conferred protection.
    Ismael AB; Hedhli D; Cérède O; Lebrun M; Dimier-Poisson I; Mévélec MN
    Vaccine; 2009 May; 27(22):2959-66. PubMed ID: 19428907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of partial protection against infection with Toxoplasma gondii genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens.
    Rosenberg C; De Craeye S; Jongert E; Gargano N; Beghetto E; Del Porto P; Vorup-Jensen T; Petersen E
    Vaccine; 2009 Apr; 27(18):2489-98. PubMed ID: 19368791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of modified live feline Toxoplasma gondii vaccine.
    Choromanski L; Freyre A; Popiel R; Brown K; Grieve R; Shibley G
    Dev Biol Stand; 1995; 84():269-81. PubMed ID: 7796964
    [No Abstract]   [Full Text] [Related]  

  • 30. Protective activity against oocyst shedding in cats vaccinated with crude rhoptry proteins of the Toxoplasma gondii by the intranasal route.
    Garcia JL; Navarro IT; Biazzono L; Freire RL; da Silva Guimarães Junior J; Cryssafidis AL; Bugni FM; da Cunha IA; Hamada FN; Dias RC
    Vet Parasitol; 2007 Apr; 145(3-4):197-206. PubMed ID: 17296268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines against Toxoplasma gondii: status, challenges and future directions.
    Liu Q; Singla LD; Zhou H
    Hum Vaccin Immunother; 2012 Sep; 8(9):1305-8. PubMed ID: 22906945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights in toxoplasmosis immunology during pregnancy. Perspective for vaccine prevention.
    Pfaff AW; Candolfi E
    Parassitologia; 2008 Jun; 50(1-2):55-8. PubMed ID: 18693558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunity to toxoplasmosis in hamsters.
    Elwell MR; Frenkel JK
    Am J Vet Res; 1984 Dec; 45(12):2668-74. PubMed ID: 6524761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mic1-3KO tachyzoite a live attenuated vaccine candidate against toxoplasmosis derived from a type I strain shows features of type II strain.
    Moiré N; Dion S; Lebrun M; Dubremetz JF; Dimier-Poisson I
    Exp Parasitol; 2009 Oct; 123(2):111-7. PubMed ID: 19508866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New molecular approaches to the diagnosis and prevention of toxoplasmosis].
    Capron A; Cesbron-Delauw MF; Darcy F
    Bull Acad Natl Med; 1990 Mar; 174(3):387-92; discussion 392-4. PubMed ID: 1696843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antigens of Toxoplasma gondii].
    Długońska H; Dytnerska K
    Wiad Parazytol; 1999; 45(4):473-80. PubMed ID: 16888988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Toxoplasma and toxoplasmosis].
    Kien T
    Ann Parasitol Hum Comp; 1991; 66 Suppl 1():46-8. PubMed ID: 1805674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxoplasma gondii: chimeric Dr fimbriae as a recombinant vaccine against toxoplasmosis.
    Gatkowska J; Gasior A; Kur J; Dlugonska H
    Exp Parasitol; 2008 Feb; 118(2):266-70. PubMed ID: 17825290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A decade of discoveries in veterinary protozoology changes our concept of "subclinical" toxoplasmosis.
    McAllister MM
    Vet Parasitol; 2005 Sep; 132(3-4):241-7. PubMed ID: 16095840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines against Toxoplasma gondii: challenges and opportunities.
    Jongert E; Roberts CW; Gargano N; Förster-Waldl E; Petersen E
    Mem Inst Oswaldo Cruz; 2009 Mar; 104(2):252-66. PubMed ID: 19430651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.